Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

Cancer Immunology Research
Brendan L HortonThomas F Gajewski

Abstract

Subsets of human tumors are infiltrated with tumor antigen-specific CD8+ T cells [tumor-infiltrating lymphocytes (TILs)] despite tumor progression. These TILs are thought to be inactivated by the immunosuppressive tumor microenvironment, through the engagement of inhibitory receptors such as CTLA-4 and PD-1. However, antigen-specific CD8+ TILs are not functionally inert but are undergoing activation in situ Here, we show that antigen-specific CD8+ TILs are actively proliferating, yet also undergo high rates of apoptosis, leading to a vicious cycle of activation and death that limits immune efficacy. Preventing CD8+ TIL apoptosis by Bcl-xL overexpression enabled accumulation and improved tumor control. Effective combination immunotherapy with an agonist 4-1BB mAb plus either CTLA-4 or PD-L1 neutralization led to a marked accumulation of specific CD8+ TILs through decreased apoptosis rather than increased T-cell entry or proliferation. Our data suggest that antigen-driven apoptosis of CD8+ TILs is a barrier to effective spontaneous antitumor immunity and should be considered as a critical factor in the development of cancer immunotherapies. Cancer Immunol Res; 6(1); 14-24. ©2017 AACR.

References

May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Justin KlineThomas F Gajewski
Sep 14, 2010·Seminars in Radiation Oncology·Thomas J Klein, Peter M Glazer
Mar 16, 2012·Nature Reviews. Cancer·Wolf Herman FridmanJérôme Galon
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Apr 27, 2013·The Journal of Clinical Investigation·Long ZhangJustin Kline
May 22, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ivan Martinez-ForeroIgnacio Melero
Sep 21, 2013·Nature Immunology·Thomas F GajewskiYang-Xin Fu
Apr 2, 2014·The Journal of Experimental Medicine·Xiaozhou FanJames P Allison
Feb 5, 2015·Journal for Immunotherapy of Cancer·Sarah E BarnesMaria-Luisa Alegre
May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 3, 2015·Proceedings of the National Academy of Sciences of the United States of America·Bettina WeigelinIgnacio Melero
Feb 24, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·César EvaristoMaria-Luisa Alegre
Jul 29, 2016·Cancer Research·Anirban BanerjeeShikhar Mehrotra
Aug 16, 2016·The Journal of Clinical Investigation·Adil I DaudMichael D Rosenblum
Nov 12, 2016·Proceedings of the National Academy of Sciences of the United States of America·Stefani SprangerThomas F Gajewski

❮ Previous
Next ❯

Citations

Sep 7, 2018·The Journal of Clinical Investigation·Priyamvada JayaprakashMichael A Curran
Jan 30, 2019·The Journal of Clinical Investigation·Tori N YamamotoChristopher A Klebanoff
Apr 12, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Derek B DanahyVladimir P Badovinac
Jun 14, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Derek B DanahyVladimir P Badovinac
Sep 22, 2019·International Journal of Molecular Sciences·Bilikis Aderonke AbolarinwaYen-Hua Huang
Dec 10, 2019·The Journal of Cell Biology·Kim Bich Nguyen, Stefani Spranger
Jan 31, 2020·International Journal of Cancer. Journal International Du Cancer·Eleonore De GuillebonEric Tartour
Mar 16, 2019·The Journal of Experimental Medicine·Bo GongRyohei Katayama
Nov 9, 2018·Cancer Immunology, Immunotherapy : CII·Jingjing ZhuBenoit J Van den Eynde
Feb 19, 2020·Nature Immunology·Brendan L Horton, Stefani Spranger
Apr 25, 2020·British Journal of Cancer·Thiago VidottoJeremy A Squire
Nov 27, 2019·Cancers·Grégory VerdeilNathalie Auphan-Anezin
Jun 12, 2020·Cellular & Molecular Immunology·Jian Qiao, Yang-Xin Fu
Jul 12, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alejo Rodriguez-VidaJoaquim Bellmunt
May 6, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ila DatarKurt A Schalper
Nov 7, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tsubasa WatanabeGabriele Niedermann
Mar 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nouf AlrasheedKwee L Yong
Jul 1, 2019·Trends in Immunology·Simone L ParkLaura K Mackay
Aug 14, 2019·Seminars in Cancer Biology·Monica MarzagalliEdwin R Manuel
Jan 26, 2021·Frontiers in Oncology·Jiaqiao FanJianxun Song
Nov 20, 2020·Journal of Experimental & Clinical Cancer Research : CR·Ze-Bo JiangElaine Lai-Han Leung
Dec 15, 2020·Cancer Medicine·Abirami SivapiragasamJeffrey S Ross
Nov 12, 2020·International Journal of Molecular Sciences·Aleksandra SimiczyjewDorota Nowak
Mar 25, 2021·Cancer Management and Research·David M RichardsAndriy Krendyukov
Dec 20, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Qinlian JiaoYun-Shan Wang
Apr 4, 2021·International Journal of Molecular Sciences·Clifford M Csizmar, Stephen M Ansell
Jun 27, 2021·Proceedings of the National Academy of Sciences of the United States of America·Iñaki EtxeberriaIgnacio Melero

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.